Nalu Medical, which is commercializing a nerve stimulation implant for chronic neuropathic pain, filed on Friday with the SEC to raise up to $100 million.
Nalu states that its miniaturized implantable pulse generator (IPG) delivers gentle electrical pulses to the nervous system to modulate pain signals to the brain, addressing unmet need for chronic neuropathic pain with clinical and practical benefits of a battery-free, minimally invasive implant. The company is targeting both spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS) indications. Its device received clearance in 2019, but Nalu delayed its commercial launch to the third quarter of 2020 due to the pandemic; in the first quarter it generated revenue of $1.4 million.
The Carlsbad, CA-based company was founded in 2014 and booked $5 million in sales for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol NALU. Nalu Medical filed confidentially on February 16, 2021. J.P. Morgan, BofA Securities, and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Pain-free investing: Nalu Medical files for a $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
